September 28, 2026
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
September 2, 2026
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 12, 2026
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
July 6, 2026
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 29, 2026
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
May 12, 2026
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
May 7, 2026
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 17, 2026
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
April 16, 2026
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
April 3, 2026
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Displaying 1 - 10 of 17